Charcot Marie Tooth Disease Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Charcot Marie Tooth Disease Overview

Charcot marie tooth disease, a hereditary neuropathy is a group of disorders that affects the motor and/or sensory peripheral nerves resulting in the muscle weakness and atrophy as well as sensory loss. The individual’s nerve cells are not able to send electrical signals properly from the brain to the muscles due to the abnormalities in the nerve axon or abnormalities in the insulation (myelin) around the axon.

“Charcot Marie Tooth Disease Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Charcot Marie Tooth Disease Market.

The Charcot Marie Tooth Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Charcot Marie Tooth Disease Pipeline Report:

• Companies across the globe are diligently working toward developing novel Charcot Marie Tooth Disease treatment therapies with a considerable amount of success over the years. Charcot Marie Tooth Disease Key players such as – DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, and others, are developing therapies for the Charcot Marie Tooth Disease treatment 

• Charcot Marie Tooth Disease Emerging therapies such as – DTx-1252, HDAC6i, GABAB PAM, IFB-088, CKD-510, EN001, Engensis , PXT3003, and others are expected to have a significant impact on the Charcot Marie Tooth Disease market in the coming years.   
• In January 2023, Néovacs and Pharnext SA announced that they have signed a financing agreement. This new agreement provides a framework for the financing of Pharnext by Néovacs under the financing and strategic support agreement announced on December 28,2022
• In May 2022, Pharnext announced new results from the ongoing open-label follow-up extension study of PXT3003 in Charcot-Marie Tooth Disease Type 1A (‘CMT1A’), the PLEO-CMT-FU trial, which followed the first double-blind, placebo controlled Phase III study, the PLEO-CMT trial
• In September 2021, Tasly Pharmaceutical Group Co., Ltd. initiated a trial titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy and Safety of PXT3003 in Charcot-Marie-Tooth Type 1A(CMT1A) Treated 15 Months”

Charcot Marie Tooth Disease Pipeline Therapeutics Assessment

• Charcot Marie Tooth Disease Assessment by Product Type
• Charcot Marie Tooth Disease By Stage and Product Type
• Charcot Marie Tooth Disease Assessment by Route of Administration
• Charcot Marie Tooth Disease By Stage and Route of Administration
• Charcot Marie Tooth Disease Assessment by Molecule Type
• Charcot Marie Tooth Disease by Stage and Molecule Type

DelveInsight’s Charcot Marie Tooth Disease Report covers around products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Emerging Charcot Marie Tooth Disease Drugs Under Different Phases of Clinical Development Include:

• DTx-1252: DTx Pharma
• HDAC6i: Augustine therapeutics
• Research programme: GABAB PAM: Addex Therapeutics
• IFB-088: InFlectis BioScience
• CKD-510: Chong Kun Dang pharmaceutical
• EN001: ENCell
• Engensis: HELIXMITH
• PXT3003: Pharnext SA

Get a Free Sample PDF Report to know more about Charcot Marie Tooth Disease Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/sample-request/charcot-marie-tooth-disease-pipeline-insight

Charcot Marie Tooth Disease Pipeline Analysis:

The Charcot Marie Tooth Disease pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Charcot Marie Tooth Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Charcot Marie Tooth Disease Treatment.
• Charcot Marie Tooth Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Charcot Marie Tooth Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Charcot Marie Tooth Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Charcot Marie Tooth Disease product details are provided in the report. Download the Charcot Marie Tooth Disease pipeline report to learn more about the emerging Charcot Marie Tooth Disease therapies

Charcot Marie Tooth Disease Pipeline Market Drivers

• Increase in prevalence of Charcot Marie Tooth Disease
• Increase in Research and development Activities

Charcot Marie Tooth Disease Pipeline Market Barriers

• Lack of FDA approved treatment
• Difficulty in diagnosis of the disease

Scope of Charcot Marie Tooth Disease Pipeline Drug Insight    

• Coverage: Global
• Key Charcot Marie Tooth Disease Companies: DTx Pharma, Augustine therapeutics, Addex Therapeutics, InFlectis BioScience, Chong Kun Dang pharmaceutical, ENCell, HELIXMITH, Pharnext SA, and others
• Key Charcot Marie Tooth Disease Therapies: DTx-1252, HDAC6i, GABAB PAM, IFB-088, CKD-510, EN001, Engensis , PXT3003, and others
• Charcot Marie Tooth Disease Therapeutic Assessment: Charcot Marie Tooth Disease current marketed and Charcot Marie Tooth Disease emerging therapies
• Charcot Marie Tooth Disease Market Dynamics: Charcot Marie Tooth Disease market drivers and Charcot Marie Tooth Disease market barriers 

Request for Sample PDF Report for Charcot Marie Tooth Disease Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Charcot Marie Tooth Disease drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services